Unigen Life Sciences Ltd., is a privately owned company. Established in 2001, Unigen Life Sciences is a research-based bio-pharmaceutical and biotechnology company dedicated to developing, manufacturing, and marketing lifestyle enhancement and rejuvenation products. Unigen Life Sciences’ portfolio also includes an extensive product line created to assist in the treatment of infertility, hypogonadisim and HIV management. We utilize various drug delivery technologies, including controlled release, trans-dermal, oral and injectable delivery systems. The Unigen Life Sciences brand has enjoyed a growing presence in the Asian region over the past seven year by pursuing a multi-layered growth strategy and strategic alliances with well-established partners.
Franklyn Prendergast has served on IDRI's Board of Directors since October of 1999. He is the Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Professor of Molecular Pharmacology and Experimental Therapeutics at the Mayo Medical School. In the past, he has served as the Director of the Mayo Clinic Cancer Center and Director of the Mayo Clinic Center for Individualized Medicine and as the Chair of the Department of Biochemistry and Molecular Biology at the Mayo Clinic. He has also served on the Board of Trustees and on the Board of Governors of the Mayo Foundation. Franklyn's research focuses on structural protein biology and bioimaging and has earned him numerous honors, including an . Just Award from the American Society of Experimental Biology and the Musgrave Gold Medal of the Institute of Jamaica. As a Rhodes Scholar, Franklyn earned his BA and his MA from Oxford University. He then went on to receive his MD from the University of the West Indies, and his PhD from the University of Minnesota. He has also received honorary DSc's from Purdue University and the University of the West Indies.